Don’t Let Australia’s R&D Tax Incentive Trigger Unintended US International Tax Cost Sharing Issues
4.13.2026Fred Adam
For US technology (including AI), pharma and medical device, biotechnology and life science companies, establishing an Australian subsidiary to access the Australian R&D Tax Incentive (RDTI)—including a refundable tax offset of up to 43.5% of eligible R&D expenditure for eligible entities with aggregated turnover below AUD 20 million—can be an effective way to partially fund clinical trials.
As a founder, you need to be scrappy, take care of that bottom-line. We get that, we’re all for a DIY approach when it makes sense (psst we even help you do that through our very free document generator). But, there is a fine line. There comes a time where you need to rope in the legal pros—a lawyer’s experience and knowledge that comes from hours and hours of advising , doing deals and even cleaning up DIY-that-went-wrong is your best bet for the long-term.
